Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01039194 | Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) | PHASE1 | COMPLETED | 18 | — | — | Jan 1, 2010 | Apr 1, 2010 | Jan 25, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| galantamine 8 mg (ER) | ACTIVE_COMPARATOR | - |
| galantamine 16 mg (ER) | ACTIVE_COMPARATOR | - |
| BMS-708163 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| galantamine | DRUG | Capsule, Oral, 8 mg (ER), once daily, Days 1-7 |
| BMS-708163 | DRUG | Capsule, Oral, 125 mg, once daily, Days 15-24 |
Inclusion Criteria: * Healthy men and postmenopausal women Exclusion Criteria: * Gastrointestinal disorders * Bleeding disorders * Peptic ulcer disease * Cholecystectomy * Seizure disorder * Asthma * Chronic obstructive pulmonary disease * Urinary tract obstruction * Cardiac conduction abnormalit...